RxDoctor Payments Data

Michael Kourany, MD

Cardiovascular Disease · Indianapolis, INNPI 1407824816

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.

$3,965in general payments, 2019–2025

Across 35 payments — averaging $113.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$920
  • Boston Scientific$763
  • Abbott$533
  • Biotronik Inc.$355
  • Edwards Lifesciences$319
  • Asahi Intecc CO., LTD.$265
  • plus $810 from 6 others
$249,772in research payments, 2019–2025

Across 132 payments — averaging $1892.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$156K
  • M.a. Med Alliance S.A.$47K
  • Shockwave Medical, Inc$29K
  • Biotronik Inc.$18K

What the payments were for

  • Food & beverage$3,953100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,965 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$157,275
Medicare patients
539
Services billed
1,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$312,668
XareltoRivaroxaban68$75,388
EntrestoSacubitril/Valsartan43$48,313
JardianceEmpagliflozin20$30,368
BrilintaTicagrelor15$9,891
Repatha SureclickEvolocumab16$9,773
Metoprolol Succinate346$5,142
Valsartan148$3,970
ClopidogrelClopidogrel Bisulfate385$3,648
Atorvastatin Calcium320$2,811
Rosuvastatin Calcium203$2,356
Isosorbide Mononitrate ErIsosorbide Mononitrate176$2,196
Prasugrel Hcl17$1,809
Ranolazine ErRanolazine15$1,684
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,654

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →